Browse by category

Preoperative Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) neither augment nor detract from metabolic and bariatric surgery (MBS), at least for the first 12 months postoperatively, according to the study by researchers from the School of Medicine, University of California, San Francisco. GLP-1 RAs use has risen dramatically with some patients treated with GLP-1 RAs1 later pursue MBS. However, the researchers noted that preoperative GLP-1 RA exposure influences post-op